Trial By Error: My Letter to Professor Moss-Morris
By David Tuller, DrPH Last week I wrote about the recently announced licensing deal between Mahana Therapeutics and King’s College London. The deal involves a web-based course of cognitive behavior therapy designed to treat irritable bowel syndrome. In a major study, the reported improvements in symptoms among participants in the web-based program were modest at […]
Lancet Psychiatry recently published the results of a high-profile trial of cognitive behavior therapy as a treatment for so-called dissociative seizures, also known as psychogenic non-epileptic seizures. The trial, nicknamed CODES, found that CBT had no impact on seizure frequency–the primary outcome. The average number of seizures per month dropped in both the treatment and […]
By David Tuller, DrPH I am slowly getting back to my efforts to highlight Mahana Therapeutics’ continuing misrepresentation of its new web-based cognitive behavior therapy program for irritable bowel syndrome. In January, the start-up company that it had licensed the program from King’s College London, based on a high-profile study published last year in Gut, […]
By David Tuller, DrPH As the world continues to wrestle with the coronavirus epidemic, President Trump is calling on us here in the US to get back to work. So I decided to start seeking answers again from Mahana Therapeutics, which announced in January that it had licensed a web-based cognitive behavior therapy program for […]
By David Tuller, DrPH In the days before coronavirus was everything, I was writing about a major study of cognitive behavior therapy for irritable bowel syndrome. The study tested telephone-delivered cognitive behavior therapy, web-based CBT against treatment-as-usual for IBS symptom severity and other more generic domains. Although the pre-COVID era feels like ancient history already, […]
By David Tuller, DrPH I have been trying to find out why Mahana Therapeutics, a San Francisco-based start-up, has chosen to disseminate misleading information about a web-based cognitive behavior therapy program for people with irritable bowel syndrome. Because Mahana’s co-founder and CEO, Rob Paull, has not responded to my letters, I have contacted some of […]
By David Tuller, DrPH Last week, I wrote to Rob Paull, the co-founder and CEO of Mahana Therapeutics, regarding the company’s misleading claims about the web-based cognitive behavior therapy program for irritable bowel syndrome it recently licensed from King’s College London. I have also written to Professor Rona Moss-Morris, the co-lead investigator of ACTIB, the […]
By David Tuller, DrPH Ten days ago, I sent a letter to Professor Rona Moss-Morris of King’s College London, seeking information about the licensing deal involving her web-based program of cognitive behavior therapy to treat irritable bowel syndrome. Since I have not heard back, this morning I made a second attempt to reach out to […]
Irritable bowel syndrome (IBS) is a common disease that affects the quality of life (QOL) and social functioning of sufferers. Visceral anxiety is currently considered a key factor in the onset and exacerbatio...
Patients in remission from inflammatory bowel disease are susceptible to irritable bowel syndrome, but diet, cognitive therapy, and medication can help treat the symptoms.Medscape Medical News
CONCLUSIONS: There is currently not enough evidence to assess whether biofeedback interventions are effective for controlling symptoms of IBS. Given the positive results reported in small trials to date, biofeedback deserves further study in people with IBS. Future research should include active control groups that use high provider-participant interaction, in an attempt to balance non-specific effects of interventions between groups, and report both commonly used outcome measures (e.g. IBS-SSS) and historical outcome measures (e.g. the composite primary symptom reduction (CPSR) score) to allow for meta-analysis with previ...